Business
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it will present two posters at the San Antonio Breast Cancer Symposium ("SABCS"), in San Antonio, TX being held at the Henry B. Gonzalez Conven
About this update from Intensity Therapeutics, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Poster PS5-08-16 Reports Early Observations from the INVINCIBLE-4 Study, an Ongoing Randomized, Presurgical Phase 2 Clinical Trial for Triple Negative Breast Cancer continue to show favorable safety ","length":198,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"50% fewer grade 3 or higher Adverse Events were observed in the INT230-6 cohort compared to the Standard of Care ("SOC") neoadjuvant chemotherapy alone cohort.","length":169,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":169,"olType":false}]},{"val":[{"type":"text","content":"Poster PS4-10-15 Describes An Overview of a Potential Phase 3 Clinical Study Design with INT230-6 plus standard of care with and without the toxic anthracycline, doxorubicin","length":173,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":540,"olType":false},{"type":"text","content":"SHELTON, Conn., Dec. 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it will present two posters at the San Antonio Breast Cancer Symposium ("SABCS"), in San Antonio, TX being held at the Henry B. Gonzalez Convention Center.","length":588,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":101,"url":"https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zdViy5pzlzPB_LdO71ooeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8","width":400,"height":101}},"href":"https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"On Friday, December 12, 2025 at 12:30 PM CST, Andreas Müller, M.D., from the Department of Medicine at the Kantonsspital W...